A.G. Goncharova1, G.A. Tikhonova2, I.N. Goncharov3

1–3 Federal State Scientific Center of the Russian Federation – Institute of Biomedical Problems RAS (Moscow, Russia)

1–3 Goncharov Dynasty Medical Center (Moscow, Russia)

Problem statement. All over the world, there is an increase in the frequency of symptoms of damage to the cardiovascular system and an increase in the risk of decompensation in patients after a SARS-CoV-2 infection. It is relevant to search for reliable markers that allow stratifying the risk of occurrence or decompensation of cardiovascular diseases with a high degree of reliability and ensuring control of the effectiveness of therapy.

The purpose of the work. Discussion of the role of cardiac markers having prognostic value in relation to the occurrence or decompensation of cardiovascular diseases after undergoing SARS-CoV-2.

Results. Based on clinical studies of the health status of 120 patients within 6 months after undergoing SARS-CoV-2, the high diagnostic value and prognostic value of individual serum markers of CCC lesion after undergoing SARS-CoV-2.. ST2 is an early predictor of damage to the cardiovascular system and a marker of the development of myocardial fibrosis, decompensation of heart failure or developing cardiomyopathy. A decrease in ST2 in response to therapy correlates with an increase in the ejection fraction of the left ventricle, a decrease in the volume of the left atrium, and is a criterion for the effectiveness of therapy.

The practical significance of the work consists in the formation of a diagnostic panel of cardiac markers reflecting the risk of decompensation of cardiovascular diseases after SARS-CoV-2. The use of a panel of protein cardiomarkers in combination with other diagnostic criteria of SARS-CoV-2 can not only increase the risk stratification of patients at different times after undergoing SARS-CoV-2, but also improve the diagnostic process, therapeutic efficacy and quality of life of patients.

Goncharova A.G., Tikhonova G.A., Goncharov I.N. The role of cardiac markers in the diagnosis of cardiovascular diseases after SARS-CoV-2. Technologies of Living Systems. 2022. V. 19. № 4. Р. 42-51. DOI: https://doi.org/10.18127/j20700997-202204-04 (In Russian)

1. COVID-19 rapid guideline: managing the long-term effects of COVID-19 NICE guideline [NG188] Published date:18 December 2020. https://www.nice.org.uk/guidance/ng188
2. WHO. 06.10.2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1
3. COVID-19 rapid guideline: managing the long-term effects of COVID-19 NICE guideline [NG188] Published date:18 December 2020. https://www.nice.org.uk/guidance/ng188
4. Diaz J.V., Soriano J.B. A Delphi consensus to advance on a Clinical Case Definition for Post COVID-19 condition: A WHO protocol. (2021) https://doi.org/10.21203/rs.3.pex-1480/v1
5. Orlova E.A., Kondratova I.G., Ogarkov O.B. Rekonvalestsenty COVID-19 imeyut gumoralnyy immunitet k belku E obo-lochki virusa SARS-CoV-2. Biomeditsinskaya radioelektronika. 2022. T. 18(3). S. 32–36. (in Russian).
6. Metodicheskiye rekomendatsii «Osobennosti techeniya Long-COVID infektsii. Terapevticheskiye i reabilitatsionnyye me-ropriyatiya» (utverzhdeny na KhVI Natsionalnom Kongresse terapevtov 18.11.2021). 2021. 217 s. (in Russian).
7. Nekrasova L.A., Nesterova O.Yu., Samokhodskaya L.M., Semina E.V., Kamalova A.A. Analiz prognosticheskoy znachimosti molekul endotelialnoy adgezii VCAM-1 i ICAM-1 v otnoshenii tyazhesti techeniya zabolevaniya u patsiyentov s COVID-19. Tekhnologii zhivykh sistem. 2022. T. 19(3). S. 5–14. (in Russian).
8. Akhmetshina M.R., Morozova M.P., Lukoshkova E.V., Ovchinnikov M.V. i dr. Zamedleniye vospaleniya i snizheniye rabotospo-sobnosti miokarda peptidom Kh. fragmentom khemoksina MCP-1. u krys v modeli ishemii-reperfuzii. Tekhnologii zhivykh sistem. 2019. № 2.
   S. 12–23. (in Russian).
9. Hendren N.S., Grodin J.L., Drazner M.H. Unique patterns of cardiovascular involvement in COVID-19. J. Card. Fail. 2020. V. 26 (6).
   P. 466–469. DOI: 10.1016/j.cardfail. 2020. 05.006
10. Karkishchenko V.N., Pomytkin I.A., Skvortsova V.I. Opioidergicheskaya sistema immunnykh kletok: novaya farmakologiche-skaya mishen v terapii «tsitokinovogo shtorma». Biomeditsinskaya radioelektronika. 2020. T. 16(4). S. 14–23. (in Russian).
11. Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020. V. 395. P. 1054–1062. DOI:10.1016/S0140-6736(20)30566-3
12. Hendren N.S., Drazner M.H., Bozkurt B., Cooper L.T. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020. V. 141 (23). P. 1903–1914. DOI: 10.1161/CIRCULATIONAHA.120.047349
13. Ciaccio M., Agnello L. Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19). Diagnosis (Berl). 2020. V. 7. № 4.
    P. 365–372.
14. Santoso A., Pranata R., Wibowo A., et al. Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: a meta-analysis //Am. J. Emerg. Med. 2021. V. 44. P. 352–357.
15. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart. J. 2016. V. 37(3). P. 267–315.
16. Garg A. et al. Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review. Cardiology. 2017.
    V. 136(3). P. 192–203.
17. Serezhina E.K., Obrezan A.G. Biomarkery povrezhdeniya i remodelirovaniya miokarda v diagnostike serdechnoy nedosta-tochnosti s sokhrannoy fraktsiyey vybrosa. RMZh. Meditsinskoye obozreniye. 2019. T. 3(10(I)). S. 23–26. (in Russian).
18. Kohli P., Bonaca M.P., Kakkar R., et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin. Chem. 2012. V. 58(1). P. 257–266. DOI: 10.1373/clinchem.2011.173369
19. Salvagno G.L., Pavan C. Prognostic biomarkers in acute coronary syndrome. Ann. Transl. Med. 2016. V. 4(13). P. 258.
    DOI: 10.21037/atm.2016.06.36
20. Zhang K., Zhang X.C., Mi Y.H., Liu J. Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction. Chin. Med. J. (Engl). 2013. V. 126(19). P. 3628–3631.
21. Ciccone M.M., Cortese F., Gesualdo M., et al. A novel cardiac bio-marker: ST2: A review. Molecules. 2013. V. 18. P. 15314–15328. DOI:10.3390/molecules181215314
22. Shah K.B., Kop W.J., Christenson R.H. et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin. Chem. 2011. V. 57. P. 874–882.
23. Breidthardt T., Balmelli C., Twerenbold R., Mosimann T., Espinola J., Haaf P. et al. Heart Failure Therapy: Induced Early ST2 Changes May Offer Long-Term Therapy Guidance. J. Card. Fail. 2013. V. 19(12). P. 821–828. DOI: 10.1016/j.cardfail.2013.11.003
24. Drapkina O.M., Kontsevaya A.V., Kravchenko A.Ya., Budnevskiy A.V., Tokmachev R.E., Chernik T.A. Biomarkery ST2 i interley-kin 33 v otsenke kardialnogo vospaleniya. fibroza i prognoza patsiyentov s khronicheskoy serdechnoy nedostatochnostyu. Rossiyskiy kardiologicheskiy zhurnal. 2021. T. 26(3S). S. 4530. https://doi.org/10.15829/1560-4071-2021-4530 (in Russian).
25. Kozhevnikova M.V., Belenkov Yu.N. Biomarkery serdechnoy nedostatochnosti: nastoyashcheye i budushcheye. Kardiologiya. 2021.
    T. 61(5). S. 4–16. (in Russian).
26. Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Colvin M.M. et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 AC-CF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017. V. 136(6). P. e137–61. DOI: 10.1161/CIR.0000000000000509
27. Quick S., Waessnig N.K., Kandler N. et al. Soluble ST2 and myocardial fibrosis in 3T cardiac magnetic resonance. Scand. Cardiovasc. J. 2015. V. 49(6). P. 361–366
28. Kim M.S., Jeong T.D., Han S.B. et al. Role of soluble ST2 as a prognostic marker in patients with acute heart failure and renal insufficiency. J. Korean. Med. Sci. 2015. V. 30(5). P. 569–575.
29. Dyleva Yu.A., Gruzdeva O.V., Akbasheva O.E., Uchasova E.G., Barbarash O.L. Fiziologicheskaya i patofiziologicheskaya rol stimuliruyushchego faktora rosta ST2. Klinicheskaya laboratornaya diagnostika. 2017. T. 62(10). S. 599–605. DOI: http://dx.doi.org/10.18821/ 0869-2084-2017-62-10-599-605 (in Russian).
30. Andreyev S.M., Adamyan L.V., Alekseyeva E.I. i dr. Vremennyye metodicheskiye rekomendatsii «Profilaktika. diagnostika i lecheniye novoy koronavirusnoy infektsii (COVID-19) Versiya 11 (07.05.2021) — Ministerstvo zdravookhraneniya Rossiyskoy Federatsii (in Russian).
31. Rekomendatsii po vedeniyu bolnykh s koronavirusnoy infektsiyey COVID-19 v ostroy faze i pri postkovidnom sindro-me v ambulatornykh usloviyakh. Pod red. prof. Vorobyeva P.A. Problemy standartizatsii v zdravookhranenii. 2021. T. 7–8. S. 3–96. https://doi.org/10.26347/1607-2502202107-08003-096 (in Russian).
32. Inciardi R.M., Adamo M., Lupi L., et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur. Heart. J. 2020. V. 41(19). P. 1821-1829. DOI:10.1093/eurheartj/ehaa388
33. Santoso A., Pranata R., Wibowo A., et al. Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: a meta-analysis. Am. J. Emerg. Med. 2021. V. 44. P. 352–357. DOI: 10.1016/j.ajem.2020.04.052
34. Boytsov S.A., Pogosova N.V., Paleyev F.N. i dr. Klinicheskaya kartina i faktory. assotsiirovannyye s neblagopriyatnymi iskhodami u gospitalizirovannykh patsiyentov s novoy koronavirusnoy infektsiyey COVID-19. Kardiologiya. 2021. T. 61(2). S. 4–14. DOI:10.18087/cardio.2021.2.n1532 (in Russian).
35. Lippi G., Lavie C.J., Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog. Cardiovasc. Dis. 2020. https://doi.org/10.1016/j.pcad.2020.03.001 [Epub ahead of print].
36. Shlyakhto E.V., Konradi A.O., Villevalde S.V. i dr. Rukovodstvo po diagnostike i lecheniyu bolezney sistemy krovoob-rashcheniya v kontekste pandemii COVID-19. Rossiyskiy kardiologicheskiy zhurnal. 2020. T. 25(3). S. 3801. DOI:10.15829/1560-4071-2020-3-3801 (in Russian)
37. Gumerov R.M., Gareyeva D.F., Davtyan P.A. i dr. Prediktornyye syvorotochnyye biomarkery porazheniya serdechno-sosudistoy sistemy pri COVID-19. Rossiyskiy kardiologicheskiy zhurnal. 2021. T. 26(S2). S. 4456. DOI:10.15829/1560-4071-2021-4456 (in Russian).
38. Lupón J., Gaggin H.K., de Antonio M. et al. Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. Int. J. Cardiol. 2015. V. 184. P. 337–343. DOI: 10.1016/j.ijcard.2015.02.019
39. Kopyeva K.V., Grakova E.V., Teplyakov A.T. Novyye markery serdechnoy nedostatochnosti: znacheniye dlya diagnostiki i pro-gnozirovaniya NT-proBNP i interleykinovykh retseptorov – chlenov semeystva st2. Kompleksnyye problemy serdechno-sosudistykh zabolevaniy. 2018. T. 7. № 1. S. 94–101. (in Russian).
40. Zagidullin N., Motloch L.J., Gareeva D. et al. Combining Novel Biomarkers for Risk Stratification of Two-Year Cardiovascular Mortality in Patients with ST-Elevation Myocardial Infarction. J. Clin. Med. 2020. V. 9(2). P. 550. DOI:10.3390/jcm9020550
41. Miftode R.S., Petriș A.O., Onofrei A.V. et al. The Novel Perspectives Opened by ST2 in the Pandemic: A Review of Its Role in the Diagnosis and Prognosis of Patients with Heart Failure and COVID-19. Diagnostics (Basel). 2021. V. 11(2). P. 175. DOI:10.3390/diagnostics11020175